• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Zydus Lifesciences Limited — Updates, 06-11-2025: Press Release

    06-11-2025 | 09:52 am

    Zydus received USFDA Orphan Drug Designation for Desidustat, targeting beta-thalassemia. This development provides potential seven-year market exclusivity post-approval, accelerating its path for this critical and underserved medical condition.

    No comments yet. Be the first to comment!

    All announcements from Zydus Lifesciences Limited